Source: PHARMAC
Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its meeting in November 2025.
Applications
Abemaciclib (branded as VERZENIO) and ribociclib (branded as KISQALI) for people with early-stage breast cancer
The Committee will discuss applications for the funding of abemaciclib and ribociclib to be used after surgery (adjuvant treatment) and alongside hormone therapy.
Olaparib (branded as Lynparza) to prevent breast cancer from returning in people with an early, high-risk form of the disease
The Committee will discuss an application for the funding of olaparib to treat people who have a cancer with a BRCA gene mutation and is HER-2 negative. Olaparib would be given to individuals after they have had surgery, with chemotherapy given before or after surgery as well.
Olaparib (branded as Lynparza) for people with metastatic breast cancer that has a certain genetic mutation
The Committee will discuss an application for the funding of olaparib to treat cancer that has spread (metastatic). It would be used to treat people who have a PALB2 genetic mutation or BRCA mutation and whose cancer is HER-2 negative.
Application for olaparib for metastatic breast cancer(external link)
Belantamab mafodotin (branded as Blenrep) for people with multiple myeloma
The Committee will discuss an application for the funding of belantamab mafodotin (Blenrep) which is used to treat people with multiple myeloma when the cancer has returned or hasn’t responded to previous treatments. It would be used after at least two previous treatments, or after at least three previous treatments.
Applications for Belantamab mafodotin
Multiple myeloma, relapsed or refractory, 2nd line or later(external link)
Multiple myeloma, relapsed or refractory, 3rd line or later(external link)
Nivolumab (branded as Opdivo), for people with lung cancer
The Committee will discuss an application for Nivolumab (Opdivo) which is used before surgery in people with non-small cell lung cancer (NSCLC). It would be used with chemotherapy for NSCLC that can be removed by surgery and is at stage IB, II or IIIA.
Application for nivolumab (with chemotherapy), for non-small cell lung cancer
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.
